Cagrilintide + Semaglutide

[Indications] It is suitable for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.

[Usage and dosage] This product is administered by subcutaneous injection once weekly. In clinical studies, the cagrilintide and semaglutide combination treatment was gradually dose-escalated to improve tolerability. The target maintenance dose studied was cagrilintide 2.4 mg combined with semaglutide 2.4 mg once weekly. Dose escalation and treatment duration should follow the specific clinical protocol or approved product information.